Literature DB >> 18824619

Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study.

E Jernberg1, A Moghaddam, H Moi.   

Abstract

There are no evidence-based guidelines for the treatment of Mycoplasma genitalium-positive genital infection. In a retrospective survey, we analysed the treatment results of patients tested for M. genitalium at Olafia, Unit for Sexual Transmitted Diseases in Oslo. Out of 10,109 patients, 452 had a positive polymerase chain reaction. Between 72% and 100% of patients in the different treatment groups returned for test of cure after four to five weeks. First-line treatment with 1 g single dose azithromycin had a recovery rate of 79%. It was as effective as an extended five-days' course of azithromycin. Ofloxacin 200 mg b.i.d for 10 days cured 56% and moxifloxacin 400 mg o.d. for seven days as either second-, third- or fourth-line treatment after azithromycin or ofloxacin failure cured 100%. Azithromycin 1 g as a single dose seems to be the best choice of treatment for M. genitalium, with moxifloxacin 400 mg x 1 for seven days if treatment fails.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824619     DOI: 10.1258/ijsa.2008.008038

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  30 in total

1.  Cervicitis of unknown etiology.

Authors:  Stephanie N Taylor
Journal:  Curr Infect Dis Rep       Date:  2014-07       Impact factor: 3.725

2.  Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.

Authors:  Kaitlin A Tagg; Neisha J Jeoffreys; Deborah L Couldwell; Jennifer A Donald; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Induced macrolide resistance in Mycoplasma genitalium isolates from patients with recurrent nongonococcal urethritis.

Authors:  Haur Sen Yew; Trevor Anderson; Edward Coughlan; Anja Werno
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

Review 5.  Mycoplasma genitalium: from Chrysalis to multicolored butterfly.

Authors:  David Taylor-Robinson; Jørgen Skov Jensen
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

6.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Authors:  Jørgen Skov Jensen; Prabhavathi Fernandes; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

Review 7.  Developing a Public Health Response to Mycoplasma genitalium.

Authors:  Matthew R Golden; Kimberly A Workowski; Gail Bolan
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

8.  Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial.

Authors:  Lisa E Manhart; Catherine W Gillespie; M Sylvan Lowens; Christine M Khosropour; Danny V Colombara; Matthew R Golden; Navneet R Hakhu; Katherine K Thomas; James P Hughes; Nicole L Jensen; Patricia A Totten
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

9.  Direct detection of macrolide resistance in Mycoplasma genitalium isolates from clinical specimens from France by use of real-time PCR and melting curve analysis.

Authors:  Arabella Touati; Olivia Peuchant; Jorgen S Jensen; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

10.  Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.

Authors:  Yuko Yamaguchi; Masaya Takei; Ryuta Kishii; Mitsuru Yasuda; Takashi Deguchi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.